in the absence of a submission from the holder of the marketing authorisation:
depemokimab (Exdensur®) is not recommended for use within NHSScotland.
Indication under review: add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice366KB (PDF)
Medicine details
- Medicine name:
- depemokimab (Exdensur)
- SMC ID:
- SMC2970
- Indication:
Add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Ear, nose and oropharynx
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 September 2026